Targeting apoptosis pathways in cancer by Chinese medicine

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 304-312

  Li Weber, Min ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Cancer; DNA damage; Drug; MAPK; NF B; ROS

Indexed keywords

ALOE EMODIN; ANTINEOPLASTIC AGENT; APIGENIN; ARTEMISININ; ARTESUNATE; BAICALEIN; BERBERINE; CALCIUM ION; CASPASE 3; CASPASE 8; CASPASE 9; CELASTROL; CHRYSIN; DEATH RECEPTOR; EMODIN; EVODIAMINE; FAS LIGAND; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROCASPASE 8; PROTEIN BAK; PROTEIN BAX; RHEIN; ROCAGLAMIDE DERIVATIVE; TRIPTOLIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; WOGONIN; X LINKED INHIBITOR OF APOPTOSIS;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL INFECTION; CANCER INHIBITION; CHINESE MEDICINE; CHRONIC INFLAMMATION; CONSTIPATION; DIARRHEA; DNA DAMAGE; DOUBLE STRANDED DNA BREAK; DRUG DNA BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DYSENTERY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; JAUNDICE; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MEDICINAL PLANT; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TRANSCRIPTION REGULATION; ULCER; VIRUS INFECTION;

ANIMALS; APOPTOSIS; DNA DAMAGE; DRUG DESIGN; HUMANS; MAP KINASE SIGNALING SYSTEM; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; NF-KAPPA B; REACTIVE OXYGEN SPECIES;

ALOE;

EID: 84876087744     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.07.015     Document Type: Article

References (67)

1. Muppidi J.R., Tschopp J., Siegel R.M. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 2004, 21:461-465.
2. Krammer P.H., Arnold R., Lavrik I. Life and death in peripheral T cells. Nat. Rev. Immunol. 2007, 7:532-542.
3. Johnstone R.W., Frew A.J., Smyth M.J. The TRAIL apoptotic pathway in cancer onset progression and therapy. Nat. Rev. Cancer 2008, 8:782-798.
4. Orrenius S., Zhivotovsky B., Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol. 2003, 4:552-565.
5. Roderick H.L., Cook S.J. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat. Rev. Cancer 2008, 8:361-375.
6. Trachootham D., Alexandre J., Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?. Nat. Rev. Drug Disc. 2009, 8:579-591.
7. Riedl S.J., Salvesen G.S. The apoptosome: signalling platform of cell death. Nat. Rev. Mol. Cell Biol. 2007, 8:405-413.
8. Billen L.P., Shamas-Din A., Andrews D.W. Bid: a Bax-like BH3 protein. Oncogene 2008, 1:93-104.
9. Eckelman B.P., Salvesen G.S., Scott F.L. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006, 7:988-994.
10. Galluzzi L., Larochette N., Zamzami N., Kroemer G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 2006, 25:4812-4830.
11. Wu H., Tschopp J., Lin S.C. Smac mimetics and TNFalpha: a dangerous liaison?. Cell 2007, 131:655-658.
12. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
13. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
14. Fulda S. Apoptosis pathways and their therapeutic exploitation in pancreatic cancer. J. Cell Mol. Med. 2009, 13:1221-1227.
15. U. Testa, TRAIL/TRAIL-R in hematologic malignancies, J. Cell Biochem., 2010 March 24 (Epub ahead of print).
16. Turrens J.F. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003, 552:335-344.
17. Szatrowski P.T., Nathan C.F. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 1991, 51:794-798.
18. Schumacker P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006, 10:175-176.
19. Huang Q., Lu G., Shen H.M., Chung M.C., Ong C.N. Anti-cancer properties of anthraquinones from rhubarb. Med. Res. Rev. 2007, 27:609-630.
20. Efferth T., Oesch F. Oxidative stress response of tumor cells: microarray-based comparison between artemisinins and anthracyclines. Biochem. Pharmacol. 2004, 68:3-10.
21. Efferth T., Giaisi M., Merling A., Krammer P.H., Li-Weber M. Artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One 2007, 2:e693.
22. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 2002, 32:1655-1660.
23. Borges F., Fernandes E., Roleira F. Progress towards the discovery of xanthine oxidase inhibitors. Curr. Med. Chem. 2002, 9:195-217.
24. Meeran S.M., Katiyar S., Katiyar S.K. Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol. Appl. Pharmacol. 2009, 229:33-43.
25. Li-Weber M. New therapeutic aspects of flavones: the anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin. Cancer Treat. Rev. 2009, 35:57-68.
26. Townsend D.M., Tew K.D., Tapiero H. The importance of glutathione in human disease. Biomed. Pharmacother. 2003, 57:145-155.
27. Kachadourian R., Day B.J. Flavonoid-induced glutathione depletion: potential implications for cancer treatment. Free Radic. Biol. Med. 2006, 41:65-76.
28. Bonner W.M., Redon C.E., Dickey J.S., Nakamura A.J., Sedelnikova O.A., Solier S., Pommier Y. GammaH2AX and cancer. Nat. Rev. Cancer 2008, 8:957-967.
29. Li P.C., Lam E., Roos W.P., Zdzienicka M.Z., Kaina B., Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res. 2008, 68:4347-4351.
30. Liu Z., Liu Q., Xu B., Wu J., Guo C., Zhu F., Yang Q., Gao G., Gong Y., Shao C. Berberine induces p53-dependent cell cycle arrest and apoptosis of human osteosarcoma cells by inflicting DNA damage. Mutat. Res. 2009, 662:75-83.
31. Lu C., Zhu F., Cho Y.Y., Tang F., Zykova T., Ma W.Y., Bode A.M., Dong Z. Cell apoptosis: requirement of H2AX in DNA ladder formation, but not for the activation of caspase-3. Mol. Cell 2006, 23:121-132.
32. Krey A.K., Hahn F.E. Berberine: complex with DNA. Science 1969, 166:755-757.
33. Wang H.G., Pathan N., Ethell I.M., Krajewski S., Yamaguchi Y., Shibasaki F., McKeon F., Bobo T., Franke T.F., Reed J.C. Ca2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 1999, 284:339-343.
34. Baumann S., Fas S.C., Giaisi M., Müller W.W., Merling A., Gülow K., Edler L., Krammer P.H., Li-Weber M. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis. Blood 2008, 111:2354-2363.
35. Montero M., Lobatón C.D., Hernández-Sanmiguel E., Santodomingo J., Vay L., Moreno A., Alvarez J. Direct activation of the mitochondrial calcium uniporter by natural plant flavonoids. Biochem. J. 2004, 384:19-24.
36. Dutta J., Fan Y., Gupta N., Fan G., Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006, 25:6800-6816.
37. Jost P.J., Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
38. Hussain S.R., Cheney C.M., Johnson A.J., Lin T.S., Grever M.R., Caligiuri M.A., Lucas D.M., Byrd J.C. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin. Cancer Res. 2007, 13:2144-2150.
39. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer. 2005, 5:297-309.
40. Zhu W., Ou Y., Li Y., Xiao R., Shu M., Zhou Y., Xie J., He S., Qiu P., Yan G. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol. Pharmacol. 2009, 75:812-819.
41. Salminen A., Lehtonen M., Paimela T., Kaarniranta K. Celastrol: Molecular targets of Thunder God Vine. Biochem. Biophys. Res. Commun. 2010, 394:439-442.
42. Sethi G., Ahn K.S., Pandey M.K., Aggarwal B.B. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 2007, 109:2727-2735.
43. Sung B., Park B., Yadav V.R., Aggarwal B.B. Celastrol, a triterpene, enhances TRAIL-induced apoptosis through the down-regulation of cell survival proteins and up-regulation of death receptors. J. Biol. Chem. 2010, 285:11498-11507.
44. Liao C.H., Pan S.L., Guh J.H., Chang Y.L., Pai H.C., Lin C.H., Teng C.M. Antitumor mechanism of evodiamine, a constituent from Chinese herb Evodiae fructus, in human multiple-drug resistant breast cancer NCI/ADR-RES cells in vitro and in vivo. Carcinogenesis 2005, 26:968-975.
45. Takada Y., Kobayashi Y., Aggarwal B.B. Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J. Biol. Chem. 2005, 280:17203-17212.
46. Gloire G., Legrand-Poels S., Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol 2006, 72:1493-1505.
47. Bubici C., Papa S., Dean K., Franzoso G. Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance. Oncogene 2006, 25:6731-6748.
48. Rice-Evans C.A., Miller N.J., Paganga G. Structure-antioxidant activity relationships of flavonoids and phenlic acids. Free Radic. Biol. Med. 1996, 20:933-956.
49. Fas S.C., Baumann S., Zhu J.Y., Giaisi M., Treiber M.K., Mahlknecht U., Krammer P.H., Li-Weber M. Wogonin sensitizes resistant malignant cells to TNFα- and TRAIL-induced apoptosis. Blood 2006, 108:3700-3706.
50. Huang S.T., Lee Y., Gullen E.A., Cheng Y.C. Impacts of baicalein analogs with modification of the 6th position of A ring on the activity toward NF-kappaB-, AP-1-, or CREB-mediated transcription. Bioorg. Med. Chem. Lett. 2008, 18:5046-5049.
51. Chou C.C., Pan S.L., Teng C.M., Guh J.H. Pharmacological evaluation of several major ingredients of Chinese herbal medicines in human hepatoma Hep3B cells. Eur. J. Pharm. Sci. 2003, 19:403-412.
52. Romano G., Giordano A. Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle. 2008, 7:3664-3668.
53. Silvera D., Formenti S.C., Schneider R.J. Translational control in cancer. Nat. Rev. Cancer 2010, 10:254-266.
54. Montagut C., Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 2009, 283:125-134.
55. Leuenroth S.J., Crews C.M. Triptolide-induced transcriptional arrest is associated with changes in nuclear substructure. Cancer Res. 2008, 68:5257-5266.
56. Pan J. RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer Lett. 2010, 292:149-152.
57. Phatnani H.P., Greenleaf A.L. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev. 2006, 20:2922-2936.
58. Kim S., Salim A.A., Swanson S.M., Kinghorn A.D. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med. Chem. 2006, 6:319-345.
59. Zhu J.Y., Lavrik I.N., Mahlknecht U., Giaisi M., Proksch P., Krammer P.H., Li-Weber M. The tradition Chinese herbal compound rocaglamide preferentially induces apoptosis in leukemia cells by modulation of MAPK activities. Int. J. Cancer 2007, 121:1839-1846.
60. Zhu J.Y., Giaisi M., Köhler R., Müller W.W., Mühleisen A., Proksch P., Krammer P.H., Li-Weber M. Rocaglamide sensitizes leukemic T cells to activation-induced cell death by differential regulation of CD95L and c-FLIP expression. Cell Death Differ. 2009, 16:1289-1299.
61. M. Bleumink, R. Köhler, M. Giaisi, P. Proksch, P.H. Krammer, M. Li-Weber, Rocaglamide breaks TRAIL-resistance in HTLV-1-associated adult T-cell leukemia/lymphoma by translational suppression of c-FLIP Expression, Cell Death Differ. (2010), in press.
62. Pang X., Yi Z., Zhang J., Lu B., Sung B., Qu W., Aggarwal B.B., Liu M. Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 2010, 70:1951-1959.
63. Taniguchi H., Yoshida T., Horinaka M., Yasuda T., Goda A.E., Konishi M., Wakada M., Kataoka K., Yoshikawa T., Sakai T. Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells. Cancer Res. 2008, 68:8918-8927.
64. Brenner D., Krammer P.H., Arnold R. Concepts of activated T cell death. Crit. Rev. Oncol. Hematol. 2008, 66:52-64.
65. Li-Weber M., Krammer P.H. Function and regulation of CD95 (APO-1/Fas) ligand in the immune system. Semin. Immunol. 2003, 15:145-157.
66. Proksch P., Giaisi M., Treiber M.K., Palfi K., Merling A., Spring H., Krammer P.H., Li-Weber M. Rocaglamide derivatives are immunosuppressive phytochemicals that target NF-AT activity in T cells. J. Immunol. 2005, 174:7075-7084.
67. Chen L., Park S.M., Tumanov A.V., Hau A., Sawada K., Feig C., Turner J.R., Fu Y.X., Romero I.L., Lengyel E., Peter M.E. CD95 promotes tumour growth. Nature 2010, 465:492-496.